Kevin W Hunt

This inventor holds 25 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Neuromuscular Disease Treatment. Top assignees: Array Biopharma Inc., Edgewise Therapeutics, Inc., Genentech, Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin W Hunt. Retrieved from https://idiyas.com/inventor/kevin-w-hunt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 9)

% Patents Active = 68.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 14)

Average Co-Inventor Count = 6.7

ph-index = 5

Forward Citations = 89(Granted Patents)

Location History:

Longmont, CO (US) (2007 - 2020)
Boulder, CO (US) (2013 - 2024)

Company Filing History:

Edgewise Therapeutics, Inc.

Edgewise Therapecutics, Inc.

patents

5. 1 out of 1,169

Vertex Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Pyridazinone Compounds

Quinazolinone Dione Compounds

Kinase Inhibitors

Serine/Threonine Kinase Inhibitors

FGFR Tyrosine Kinase Inhibitors

Phenoxychroman Derivatives

Macrocyclic Analogs

Immunoregulatory Disorders

Respiratory Diseases

Phosphatase Inhibitors

Dihydroquinazolinone Compounds

Quinolinone Amide Compounds

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643892 - Pyridazinone compounds for the treatment of neuromuscular diseases (2026-06-02),

2. 12559464 - Quinazolinone dione compounds and uses thereof (2026-02-24),

3. 12509431 - 1,4-dihydroquinazolinone compounds and uses thereof (2025-12-30),

4. 12448369 - Quinolinone amide compounds and uses thereof (2025-10-21),

5. 12415794 - Pyridazinone compounds and uses thereof (2025-09-16),

6. 12240833 - Pyridazinone compounds and uses thereof (2025-03-04),

7. 12240831 - Pyridazinone compounds and uses thereof (2025-03-04),

8. 12012395 - Pyridazinone compounds and uses thereof (2024-06-18),

9. 11390606 - Pyridazinone compounds and uses thereof (2022-07-19),

10. 11236065 - Pyridazinone compounds and uses thereof (2022-02-01),

11. 11091464 - Pyridazinone compounds and uses thereof (2021-08-17),

12. 10766881 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2020-09-08),

13. 10208024 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2019-02-19),

14. 10154995 - Serine/threonine kinase inhibitors (2018-12-18),

15. 9763942 - Serine/threonine kinase inhibitors (2017-09-19),

Title: Kevin W. Hunt: Innovator in Neuromuscular Disease Treatment

Introduction: Kevin W. Hunt, based in Longmont, Colorado, is an accomplished inventor with a remarkable portfolio of 21 patents. His contributions primarily lie in the field of pharmacology, particularly aimed at addressing neuromuscular diseases.

Latest Patents: Among Hunt's recent inventions is a series of patents concerning substituted pyridazinone compounds. These innovative compounds and their associated pharmaceutical compositions have been specifically designed for the treatment of neuromuscular diseases like Duchenne Muscular Dystrophy (DMD). The disclosed compounds not only aim to treat DMD but also play a crucial role in modulating inflammatory inhibitors such as IL-1, IL-6, and TNF-α.

Career Highlights: Throughout his career, Kevin W. Hunt has made significant advancements in his field while working with notable companies, including Array Biopharma Inc. and Edgewise Therapeutics, Inc. His role in these organizations has allowed him to focus on innovative solutions for complex medical conditions.

Collaborations: Kevin has collaborated with esteemed colleagues, including Adam Wade Cook and Laurence Edward Burgess, emphasizing the importance of teamwork in driving forward significant pharmaceutical innovations.

Conclusion: Kevin W. Hunt's dedication to innovating treatment methods for neuromuscular diseases makes him a prominent figure in the field. His extensive patent portfolio reflects his commitment to improving patient outcomes through cutting-edge research and development.

Profile summary based on public USPTO records.